Get the Stockscreener App
57.63
0.03%
-0.02
After Hours:
56.87
-0.76
-1.32%
Sanofi Adr stock is traded at $57.63, with a volume of 1.33M.
It is down -0.03% in the last 24 hours and up +2.44% over the past month.
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
See More
Previous Close:
$57.65
Open:
$57.83
24h Volume:
1.33M
Relative Volume:
0.71
Market Cap:
$144.47B
Revenue:
$51.29B
Net Income/Loss:
$4.58B
P/E Ratio:
18.16
EPS:
3.1735
Net Cash Flow:
$15.63B
1W Performance:
+0.35%
1M Performance:
+2.44%
6M Performance:
+18.58%
1Y Performance:
+7.44%
1-Day Range:
$57.31
$57.88
1-Week Range:
$56.43
$57.91
52-Week Range:
$42.63
$58.97
Sanofi Adr Stock (SNY) Company Profile
Name
Sanofi Adr
Sector
Industry
Phone
-
Address
-
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-05-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-30-23 | Downgrade | Stifel | Buy → Hold |
| Sep-06-23 | Upgrade | Berenberg | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-28-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-27-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-13-22 | Resumed | Morgan Stanley | Overweight |
| Aug-12-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-09-22 | Downgrade | UBS | Buy → Neutral |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Sep-27-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-15-21 | Initiated | Deutsche Bank | Sell |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Mar-17-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-11-20 | Upgrade | Goldman | Neutral → Buy |
| Feb-11-20 | Initiated | SVB Leerink | Mkt Perform |
| Jan-06-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-20-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-03-19 | Initiated | Bernstein | Outperform |
| Aug-14-19 | Upgrade | UBS | Neutral → Buy |
| Dec-11-18 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Mar-23-18 | Upgrade | Liberum | Hold → Buy |
| Jan-23-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-06-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-01-17 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Nov-15-17 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-30-17 | Upgrade | HSBC Securities | Reduce → Hold |
View All
Sanofi Adr Stock (SNY) Latest News
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease - Benzinga
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent - Investor's Business Daily
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) - GlobeNewswire Inc.
Press Release: Availability of the Q3 2024 Aide mémoire - GlobeNewswire Inc.
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market - Benzinga
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff - Benzinga
Communiqué de presse France : Sanofi devient membre fondateur de la Fondation de l’Université Paris-Saclay et apporte son soutien financier dans le cadre d’une convention de mécénat - GlobeNewswire Inc.
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant - GlobeNewswire Inc.
Company’s Banking Stock: Dissecting a 21.83% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Is Recursion Pharmaceuticals Stock a Buy? - The Motley Fool
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years - Benzinga
Ratio Analysis: Unpacking Sanofi ADR (SNY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Market Analysts see Sanofi ADR [SNY] gaining to $60. Time to buy? - The DBT News
Should You Buy Novavax Stock After This Regulatory Win? - The Motley Fool
Questex’s Fierce Pharma Announces the 2024 Fierce Pharma Marketing Awards Winners - GlobeNewswire Inc.
Global Buccal Drug Delivery Systems Market Research 2024-2030 Featuring Johnson & Johnson, Pfizer, Sanofi, Novartis, Bayer, Teva Pharmaceuticals, AbbVie, Cipla, and Haleon - GlobeNewswire Inc.
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease - Benzinga
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU - GlobeNewswire Inc.
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU) - GlobeNewswire Inc.
GSK's Respiratory Drug Nucala Meets Goal in COPD Study - Benzinga
$12.5 Bn Influenza Vaccine Market to 2032 by Vaccine Type, Technology, Age Group, Route of Administration, and Region - GlobeNewswire Inc.
mHealth Market is expected to reach a revenue of USD 210.8 Bn by 2033, at 12.1% CAGR: Dimension Market Research - GlobeNewswire Inc.
Pseudarthrosis Treatment Market is Projected to Reach $1.37 Billion at a CAGR 4.6% by 2034 | Fact.MR Report - GlobeNewswire Inc.
Sanofi ADR Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Why Sanofi Stock Was Robustly Healthy Today - The Motley Fool
Sanofi on Track for Record High Close — Data Talk - Morningstar
Liver Fibrosis Market Is Expected to Reach USD 43.98 Billion By 2030 - GlobeNewswire Inc.
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High - The Motley Fool
Global GLP-1 Analogues Market Report 2024-2032: Market Expansion Driven by Innovation and Efficacy in Diabetes and Obesity Treatment - GlobeNewswire Inc.
Simtra BioPharma Solutions ernennt Dr. Lidia Serina zum Head of Development Services - GlobeNewswire Inc.
Multiple Sclerosis (MS) Diagnosis and Treatment Market Size to Reach USD 30.28 Bn by 2032 - GlobeNewswire Inc.
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy? - The Motley Fool
Sanofi on Pace for Highest Close Since April 2023 — Data Talk - Morningstar
Cancer Cachexia Market Forecasted to Reach $3.14 Billion by 2028 with a CAGR of 6.2% - GlobeNewswire Inc.
Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - GlobeNewswire Inc.
Biotech Stocks To Watch: Track The Latest News On Pharmaceutical Stocks And Drug Companies - Investor's Business Daily
Why AnaptysBio Was Such a Healthy Stock This Week - The Motley Fool
Targeted Therapeutics Market is Pioneering Growth Towards a USD 118.6 Billion Milestone by 2031, with a CAGR of 6.4% - GlobeNewswire Inc.
Sanofi ADR (SNY) Stock: A Year of Decreases and Increases - The InvestChronicle
Global Medical Nutrition Market Size Anticipated to Surge Past USD 26,555.9 Million Valuation by 2034, Growing at an Average 6.4% CAGR | Future Market Insights, Inc. - GlobeNewswire Inc.
Solid Organ Transplant Market is Projected to Grow at a 4.9% CAGR, Reaching $7.88 Billion by 2034 | Fact.MR Report - GlobeNewswire Inc.
UK Patient's Perspective on the Corporate Reputation of Pharma, 2023-2024 - GlobeNewswire Inc.
Top Biotech Catapults Higher As Sanofi Takes A Stake - Investor's Business Daily
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering - GlobeNewswire Inc.
Glp-1 Analogues Market Size & Share to be Worth USD 606.3 Billion by 2034, at 33% CAGR: Prophecy Market Insights - GlobeNewswire Inc.
Sanofi ADR Earns Relative Strength Rating Upgrade - Investor's Business Daily
Active Pharmaceutical Ingredients Market Size Worth $421.56 Billion by 2033: The Brainy Insights - GlobeNewswire Inc.
Biotechnology Market Size and Growth | USD 4.25 Trillion by 2033 - GlobeNewswire Inc.
Regeneron (REGN) Q2 Earnings Gain From Eylea HD, Dupixent - Zacks Investment Research
How Should You Play AstraZeneca (ABBV) After Q2 Beat, View Raise? - Zacks Investment Research
Global Mother and Child Healthcare Market Size To Worth USD 2106.78 Billion by 2033 | CAGR of 11.28% - GlobeNewswire Inc.
Sanofi Adr Stock (SNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):